Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775476 · ClinicalTrials.gov registry record · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by State University of New York - Upstate Medical University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 290
- Enrollment target
- 8
- Study locations
NCT00775476 is a Phase 2 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by State University of New York - Upstate Medical University. The registered enrollment target is 290 participants, below the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (23% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT00775476, a Phase 2 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by State University of New York - Upstate Medical University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 290 participants
- Enrollment target
- 8
- Study locations
Study Summary
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change with the elevation of the mitochondrial transmembrane potential. This study will titrate to tolerance during an initial 3 month open label period and then subjects will be randomized to one of 2 arms. It was determined by statistical analysis that each group must have 105 subjects. All subjects will be enrolled and evaluated for tolerance of NAC between dosages of 2.4 g/day and 4.8 g/day for 3 months. After A 3-month open-label dose-titration phase, SLE subjects will be randomized into 2 groups of 105 subjects either to continue the tolerated dosage of NAC or switched to equal number of placebo capsules. There will be up to seven study visits per SLE subject, including the screening and wash out visits. Visits 2-6 will be scheduled three months apart. The study will last 13 months with the wash-out visit. Each subject will donate approximately 100 ml of blood for biomarker studies at each visit. Healthy control subjects will donate blood at the same time. They will be matched to the SLE subjects by gender, age within 10 years, and ethnicity. Their blood will be used as reference for biomarker assays. There is a consent form required to participate in the phase II study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG N-acetylcysteine
Study Locations (8)
New York
- Hospital for Special Surgery - New York
- SUNY Upstate Medical University - Syracuse
Pennsylvania
- St. Luke's University Health Network - Allentown
- Penn State MS Hershey Medical Center - Hershey
California
- Cedars-Sinai Medical Center - Los Angeles
Connecticut
- Yale Center for Clinical Investigation - New Haven
Ohio
- The Ohio State University - Columbus
Oklahoma
- VA Medical Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00775476
The ClinicalTrials.gov registry entry for NCT00775476 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (23% lower). The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00775476 reports 8 study locations spanning 6 distinct geographic areas - top geographies include New York, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT00775476 about?
NCT00775476 is a clinical study titled "Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine". Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathion...
What is the current status of trial NCT00775476?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 290 participants. The study started on 2022-05-05. Estimated completion is 2028-09-30.
What conditions does trial NCT00775476 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT00775476?
The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT00775476?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00775476 being conducted?
This trial has 8 study locations across California, Connecticut, New York, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.